Alerts will be sent to your verified email
Verify Email
NECLIFE
|
Nectar Lifesciences
|
Shilpa Medicare
|
Hikal
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
API Sector
|
|||
|
Global DMFs filed
|
101.0 . | n/a | n/a |
|
Pharmaceutical Sector
|
|||
|
Number of ANDA's Filed in USA
|
15.0 . | 30.0 . | n/a |
|
R&D as a % of Total Sales
|
1.01 % | 4.68 % | 4.0 % |
|
Financials
|
|||
|
5 yr Average ROE
|
0.06 % | 6.52 % | 12.04 % |
|
5yr average Equity Multiplier
|
2.25 | 1.57 | 2.23 |
|
5yr Average Asset Turnover Ratio
|
0.8 | 0.4 | 0.84 |
|
5yr Avg Net Profit Margin
|
-0.35 % | 10.22 % | 6.39 % |
|
Price to Book
|
0.72 | 2.94 | 3.2 |
|
P/E
|
95.13 | 0.0 | 51.2 |
|
5yr Avg Cash Conversion Cycle
|
105.68 Days | 113.38 Days | 44.89 Days |
|
Inventory Days
|
130.91 Days | 103.45 Days | 66.84 Days |
|
Days Receivable
|
75.92 Days | 123.51 Days | 79.34 Days |
|
Days Payable
|
104.38 Days | 118.45 Days | 84.24 Days |
|
5yr Average Interest Coverage Ratio
|
0.97 | 18.78 | 4.97 |
|
5yr Avg ROCE
|
8.4 % | 7.32 % | 15.64 % |
|
5yr Avg Operating Profit Margin
|
8.6 % | 20.63 % | 17.42 % |
|
5 yr average Debt to Equity
|
0.77 | 0.37 | 0.72 |
|
5yr CAGR Net Profit
|
n/a | n/a | -5.33 % |
|
5yr Average Return on Assets
|
-0.03 % | 4.28 % | 5.39 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
55.8 % | 50.01 % | 68.85 % |
|
Share Pledged by Promoters
|
100.0 % | 90.41 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -3.24 % | 0.08 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | -1.36 % | 2.58 % |
|
Nectar Lifesciences
|
Shilpa Medicare
|
Hikal
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
